Download announcement as PDF
Thor Medical ASA - Share Capital Increase in Relation to the Private Placement and the Retail Offering is Registered
2026-09-10 10:09:55
10.9.2026 10:09:37 CEST | Thor Medical ASA | Total number of voting rights and
capital
Oslo, Norway, 10 September 2026: Reference is made to stock exchange
announcements by Thor Medical ASA (the "Company") on 3 September 2026 regarding
the completion of a private placement of 60,260,000 new shares at a subscription
price of NOK 4.80 per share, raising gross proceeds of approx. NOK 289.2 million
(the "Private Placement"), and a retail offering of 2,240,000 new shares at a
subscription price of NOK 4.80 per share, facilitated by Nordnet Bank AB,
raising gross proceeds of approx. NOK 10.8 million (the "Retail Offering").
The Private Placement and the Retail Offering raised aggregate gross proceeds of
NOK 300 million.
The share capital increases relating to the Private Placement and the Retail
Offering are now registered with the Norwegian Register of Business Enterprises.
The Company's share capital is after the registration NOK 84,500,364 divided
into 422,501,820 shares. Each share has a nominal value of NOK 0.20 and
represents one vote in the Company's general meeting.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.
CONTACTS
Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, Thor
Medical ASA, +47 988 05 724, mathias.reierth@thormedical.com -
brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is a leading supplier of high-purity isotopes to the
radiopharmaceutical industry. The Company's proprietary production platform
combines advanced separation technology with industrial-scale manufacturing
capacity to deliver a reliable, scalable and cost-efficient supply of
alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical
companies from early-stage development to commercialization, enabling scale-up
of next-generation targeted cancer therapies. Thor Medical's product portfolio
includes lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and
radium-224 (Ra-224). Based on naturally occurring thorium, Thor Medical's
production process requires neither irradiation nor nuclear reactors, providing
significant cost advantages while minimizing radioactive waste. Thor Medical is
headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the
ticker symbol TRMED. For more information, visit https://www.thormedical.com/.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19058987/17095/Download%20announc
ement%20as%20PDF.pdf
tb.no/ir-files/17848634/19058987/17095/Download%20announc\
ement%20as%20PDF.pdf\